Posted by Michael Wonder on 15 May 2017
Proposal to list bendamustine hydrochloride
15 May 2017 - PHARMAC is seeking feedback on a proposal to list bendamustine hydrochloride (Ribomustin) through a provisional agreement with Janssen-Cilag.
Details of the proposal are set out below, in summary, if progressed, it would result in bendamustine hydrochloride being funded for chronic lymphocytic leukaemia and indolent, low-grade lymphoma subject to restrictions, from 1 July 2017.
